PDF(Pubmed)
Abstract：
UNASSIGNED: Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class in other substance use disorders, and self-report surveys suggest they may result in positive outcomes for CUD. Herein, we review the existing literature pertaining to psychedelic use in persons with or at risk for CUD and consider the potential rationale underpinning psychedelics as a treatment for CUD.
UNASSIGNED: A systematic search was performed in several databases. Inclusion criteria were primary research reporting use of psychedelics or related substances and CUD for treatment in human subjects. Exclusion criteria were results including psychedelics or related substances without changes in cannabis use or risks associated with CUD.
UNASSIGNED: Three hundred and five unique results were returned. One article was identified using the non-classical psychedelic ketamine in CUD; three articles were identified as topically relevant based on their secondary data or consideration of mechanism. Additional articles were reviewed for purposes of background, review of safety considerations, and formulating rationale.
UNASSIGNED: Limited data and reporting are available on the use of psychedelics in persons with CUD, and more research is needed given the anticipated increase in CUD incidence and increasing interest in psychedelic use. While psychedelics, broadly, have a high therapeutic index with infrequent serious adverse effects, particular adverse effects at risk in the CUD population, such as psychosis and cardiovascular events, should be considered. Possible mechanisms by which psychedelics have therapeutic potential in CUD are explored.
UNASSIGNED: A systematic search was performed in several databases. Inclusion criteria were primary research reporting use of psychedelics or related substances and CUD for treatment in human subjects. Exclusion criteria were results including psychedelics or related substances without changes in cannabis use or risks associated with CUD.
UNASSIGNED: Three hundred and five unique results were returned. One article was identified using the non-classical psychedelic ketamine in CUD; three articles were identified as topically relevant based on their secondary data or consideration of mechanism. Additional articles were reviewed for purposes of background, review of safety considerations, and formulating rationale.
UNASSIGNED: Limited data and reporting are available on the use of psychedelics in persons with CUD, and more research is needed given the anticipated increase in CUD incidence and increasing interest in psychedelic use. While psychedelics, broadly, have a high therapeutic index with infrequent serious adverse effects, particular adverse effects at risk in the CUD population, such as psychosis and cardiovascular events, should be considered. Possible mechanisms by which psychedelics have therapeutic potential in CUD are explored.
摘要：
■大麻使用障碍（CUD）在美国约2-5％的成年人中普遍存在，并且随着大麻限制的减少和大麻产品中四氢大麻酚（THC）含量的增加，预计会增加。目前尚无FDA批准的CUD药物，尽管有数十种重新用途和新药的试验。迷幻药作为其他物质使用障碍的治疗类已经引起了人们的兴趣，自我报告调查表明，他们可能会导致CUD的积极结果。在这里，我们回顾了现有的关于在有CUD或有CUD风险的人群中使用迷幻药的文献,并考虑了作为CUD治疗基础的潜在理由.
■在多个数据库中进行了系统搜索。纳入标准是报告在人类受试者中使用迷幻药或相关物质和CUD进行治疗的主要研究。排除标准是包括迷幻药或相关物质的结果，而大麻使用或与CUD相关的风险没有变化。
■返回了三百五个独特的结果。在CUD中使用非经典迷幻氯胺酮鉴定了一篇文章；根据其次要数据或对机制的考虑，将三篇文章确定为局部相关。出于背景目的，对其他文章进行了审查，审查安全考虑因素，并制定理由。
■关于在CUD患者中使用迷幻药的数据和报告有限，考虑到CUD发病率的预期增加和对迷幻药物使用的兴趣增加，还需要更多的研究。虽然迷幻药，广泛地说，有较高的治疗指数与罕见的严重不良反应，在CUD人群中处于危险之中的特别不利影响，如精神病和心血管事件，应该考虑。探讨了迷幻药在CUD中具有治疗潜力的可能机制。
■在多个数据库中进行了系统搜索。纳入标准是报告在人类受试者中使用迷幻药或相关物质和CUD进行治疗的主要研究。排除标准是包括迷幻药或相关物质的结果，而大麻使用或与CUD相关的风险没有变化。
■返回了三百五个独特的结果。在CUD中使用非经典迷幻氯胺酮鉴定了一篇文章；根据其次要数据或对机制的考虑，将三篇文章确定为局部相关。出于背景目的，对其他文章进行了审查，审查安全考虑因素，并制定理由。
■关于在CUD患者中使用迷幻药的数据和报告有限，考虑到CUD发病率的预期增加和对迷幻药物使用的兴趣增加，还需要更多的研究。虽然迷幻药，广泛地说，有较高的治疗指数与罕见的严重不良反应，在CUD人群中处于危险之中的特别不利影响，如精神病和心血管事件，应该考虑。探讨了迷幻药在CUD中具有治疗潜力的可能机制。
